» Articles » PMID: 33767669

Impaired Intestinal Barrier and Tissue Bacteria: Pathomechanisms for Metabolic Diseases

Overview
Specialty Endocrinology
Date 2021 Mar 26
PMID 33767669
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

An intact intestinal barrier, representing the interface between inner and outer environments, is an integral regulator of health. Among several factors, bacteria and their products have been evidenced to contribute to gut barrier impairment and its increased permeability. Alterations of tight junction integrity - caused by both external factors and host metabolic state - are important for gut barrier, since they can lead to increased influx of bacteria or bacterial components (endotoxin, bacterial DNA, metabolites) into the host circulation. Increased systemic levels of bacterial endotoxins and DNA have been associated with an impaired metabolic host status, manifested in obesity, insulin resistance, and associated cardiovascular complications. Bacterial components and cells are distributed to peripheral tissues the blood stream, possibly contributing to metabolic diseases by increasing chronic pro-inflammatory signals at both tissue and systemic levels. This response is, along with other yet unknown mechanisms, mediated by toll like receptor (TLR) transduction and increased expression of pro-inflammatory cytokines, which in turn can further increase intestinal permeability leading to a detrimental positive feedback loop. The modulation of gut barrier function through nutritional and other interventions, including manipulation of gut microbiota, may represent a potential prevention and treatment target for metabolic diseases.

Citing Articles

Intestinal Microbiota Dysbiosis Role and Bacterial Translocation as a Factor for Septic Risk.

Charitos I, Scacco S, Cotoia A, Castellaneta F, Castellana G, Pasqualotto F Int J Mol Sci. 2025; 26(5).

PMID: 40076650 PMC: 11900423. DOI: 10.3390/ijms26052028.


Dysbiosis and extraintestinal cancers.

He R, Qi P, Shu L, Ding Y, Zeng P, Wen G J Exp Clin Cancer Res. 2025; 44(1):44.

PMID: 39915884 PMC: 11804008. DOI: 10.1186/s13046-025-03313-x.


Cardiovascular protective effects of natural flavonoids on intestinal barrier injury.

Zhou P, Xu H, Wang L Mol Cell Biochem. 2025; .

PMID: 39820766 DOI: 10.1007/s11010-025-05213-2.


Evaluating the Effects of Sugar Shift Symbiotic on Microbiome Composition and LPS Regulation: A Double-Blind, Placebo-Controlled Study.

Garcia G, Soto J, Netherland Jr M, Hasan N, Buchaca E, Martinez D Microorganisms. 2025; 12(12.

PMID: 39770729 PMC: 11678924. DOI: 10.3390/microorganisms12122525.


Type III Secretion System in Intestinal Pathogens and Metabolic Diseases.

Zhou L, Zhang Y, Wu S, Kuang Y, Jiang P, Zhu X J Diabetes Res. 2024; 2024:4864639.

PMID: 39544522 PMC: 11561183. DOI: 10.1155/2024/4864639.


References
1.
Massier L, Chakaroun R, Kovacs P, Heiker J . Blurring the picture in leaky gut research: how shortcomings of zonulin as a biomarker mislead the field of intestinal permeability. Gut. 2020; 70(9):1801-1802. PMC: 8355880. DOI: 10.1136/gutjnl-2020-323026. View

2.
Frampton J, Murphy K, Frost G, Chambers E . Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function. Nat Metab. 2020; 2(9):840-848. DOI: 10.1038/s42255-020-0188-7. View

3.
Saltiel A, Olefsky J . Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017; 127(1):1-4. PMC: 5199709. DOI: 10.1172/JCI92035. View

4.
Lammers K, Lu R, Brownley J, Lu B, Gerard C, Thomas K . Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008; 135(1):194-204.e3. PMC: 2653457. DOI: 10.1053/j.gastro.2008.03.023. View

5.
McNelis J, Lee Y, Mayoral R, van der Kant R, Johnson A, Wollam J . GPR43 Potentiates β-Cell Function in Obesity. Diabetes. 2015; 64(9):3203-17. PMC: 4542437. DOI: 10.2337/db14-1938. View